SYNTHELIS and PEACCEL have signed a strategic partnership to offer their clients a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery
As of 12th April 2022, PEACCEL and SYNTHELIS combine their know-how and thus capitalize on their respective technologies in developing a joint offer, to respond to the needs of their customers and partners. This joint offer combines the innov’SAR industrial AI platform developed by PEACCEL and the cell-free expression technology and expertise provided by SYNTHELIS.
